Tirzepatide 10mg
Dual GIP/GLP-1 receptor agonist — starter vial for early titration phases.
Tap a strength to switch — price, image & stock update automatically
Key Benefits
activates two complementary incretin pathways for superior metabolic response vs GLP-1 monotherapy
SURMOUNT-1 demonstrated 22.5% mean body weight reduction at 72 weeks, the highest of any approved weight-loss drug
reduces HbA1c by up to 2.46% in T2D research models, outperforming semaglutide in head-to-head trials
dual receptor activation produces stronger satiety signaling than single-receptor GLP-1 agonists
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
Tirzepatide is a 39-amino acid peptide with a C20 fatty diacid chain enabling albumin binding and a ~5-day half-life. It acts as a dual agonist at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP receptor activation adds complementary metabolic effects — enhanced insulin secretion, reduced glucagon, and direct adipocyte signaling — producing greater weight reduction than GLP-1 agonism alone.
Research Highlights
- SURMOUNT-1 trial: 22.5% mean body weight reduction at 15 mg/week over 72 weeks — the highest of any approved weight-loss drug at time of publication
- SURPASS-2 trial: tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1 mg
- FDA approved as Mounjaro (T2D) in 2022 and Zepbound (obesity) in 2023
- Dual receptor mechanism produces additive metabolic effects beyond GLP-1 monotherapy
Randomised controlled trial data available. Results are compound-specific and do not constitute treatment guidance.
For laboratory research only
All Research Systems →For research use only — not for human consumption. No treatment claims.
Full Research Hub →How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 10mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Tirzepatide is a 39-amino acid peptide with a C20 fatty diacid chain enabling albumin binding and a ~5-day half-life. It acts as a dual agonist at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP receptor activation adds complementary metabolic effects — enhanced insulin secretion, reduced glucagon, and direct adipocyte signaling — producing greater weight reduction than GLP-1 agonism alone.
Clinical Context
Tirzepatide represents the second generation of incretin-based therapy. Its dual mechanism — acting on both GIP and GLP-1 receptors — produces metabolic effects that exceed GLP-1 monotherapy in head-to-head trials. The 10mg vial is designed for the initial titration phases (2.5 mg and 5 mg/week) before advancing to higher maintenance doses.
Research Highlights
- SURMOUNT-1 trial: 22.5% mean body weight reduction at 15 mg/week over 72 weeks — the highest of any approved weight-loss drug at time of publication
- SURPASS-2 trial: tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1 mg
- FDA approved as Mounjaro (T2D) in 2022 and Zepbound (obesity) in 2023
- Dual receptor mechanism produces additive metabolic effects beyond GLP-1 monotherapy
Storage & Reconstitution
Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States